Heart failure with improved ejection fraction in patients with tachycardia-induced cardiomyopathy: a case report
https://doi.org/10.20996/1819-6446-2023-2875
EDN: UZDNTF
Abstract
Heart failure and arrhythmias are pathogenetically closely interconnected and they are mutually aggravating each other. At the same time, tachycardia-induced cardiomyopathy is particularly a reversible disease with proper treatment. This article presents a case report of an elderly patient with hypertension and atrial fibrillation, which are associated to an advanced heart failure and complicating the management of a decreasing kidneys filtration capacity, hematuria and brain stroke. In this case report, tachycardia-induced cardiomyopathy is caused by persistent atrial fibrillation. A complex approach to diagnosis and evidence-based treatment (in particular cardioversion and radiofrequency ablation) made it possible to restore sinus rhythm and compensate heart failure. Dynamics of the clinical state of the patient, laboratory indicators, echocardiographic characteristics allowed us to retrospectively verify atrial fibrillation-mediated cardiomyopathy as the main cause of heart failure progression, and classify this clinical case as heart failure with improved ejection fraction.
About the Authors
E. A. Pravkina
Ryazan State Medical University
Russian Federation
Russian Federation
Ekaterina A. Pravkina
E. N. Kochnova
Ryazan State Medical University
Russian Federation
Russian Federation
Evgenia N. Kochnova
K. G. Pereverzeva
Ryazan State Medical University
Russian Federation
Russian Federation
Kristina G. Pereverzeva
S. S. Yakushin
Ryazan State Medical University
Russian Federation
Russian Federation
Sergey S. Yakushin
References
1. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021;23(3):352-380. DOI:10.1002/ejhf.2115.
2. Merlo M, Caiffa T, Gobbo M, et al. Reverse Remodeling in Dilated Cardiomyopathy. J Am Coll Cardiol. 2011;57(13):1468-76. DOI:10.1016/j.jacc.2010.11.030.
3. Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014;129(23):23807. DOI:10.1161/CIRCULATIONAHA.113.006855.
4. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145-155. DOI:10.1002/clc.23321.
5. Huizar JF, Ellenbogen KA, Tan AY, et al. Arrhythmia-induced cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(18):2328-2344. DOI:10.1016/j.jacc.2019.02.045.
6. Albakri A. Tachycardia-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of diagnosis and clinical management method. Integr Mol Med. 2018;5:1-13. DOI:10.15761/IMM.1000324.
7. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: mechanisms and clinical applications. Pacing Clin Electrophysiol. 1996;19(1):95-106. DOI:10.1111/j.1540-8159.1996.tb04796.x.
8. Chaulin AM, Duplyakov DV. Increased natriuretic peptides not associated with heart failure. Russian Journal of Cardiology. 2020;25(4S):4140 (In Russ.) DOI:10.15829/1560-4071-2020-4140.
9. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-e646. DOI:10.1161/CIR.0000000000000455.
10. Báez Cabanillas MV, Colque R, Tibaldi MÁ, et al. Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Drugs Context. 2023;12:2022-8-4. DOI: 10.7573/dic.2022-8-4.
11. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (In Russ.) DOI:10.15829/1560-4071-2020-4083.
12. Mueller KAL, Heinzmann D, Klingel K, et al. Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol. 2017;69(17):2160-72. DOI:10.1016/j.jacc.2017.02.049.
13. Orlov OS, Bogdanova AA, Shchekochikhin DYu, et al. Long-term prognosis in patients with tachycardiainduced cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2022;15(5):508–513 (In Russ.) DOI:10.17116/kardio202215051508.
14. Nikulina NN. Actualization of positions of gliflozins in treatment algorithms for patients with heart failure: chronology of success. I. P. Pavlov Russian Medical Biological Herald. 2022;30(3):411–421 (In Russ.) DOI:10.17816/PAVLOVJ109598.
15. Wilcox JE, Fang JC, Margulies KB, et al. Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020;76(6):719-734. DOI:10.1016/j.jacc.2020.05.075.
Supplementary files
Review
For citations:
Pravkina E.A., Kochnova E.N., Pereverzeva K.G., Yakushin S.S. Heart failure with improved ejection fraction in patients with tachycardia-induced cardiomyopathy: a case report. Rational Pharmacotherapy in Cardiology. 2023;19(3):270-276. (In Russ.) https://doi.org/10.20996/1819-6446-2023-2875. EDN: UZDNTF
Views:
434
Email this article 